Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

ClinicalTrials.gov ID: NCT00847613

Public ClinicalTrials.gov record NCT00847613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.

Study identification

NCT ID
NCT00847613
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
800 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2009 (Type not available)
Primary completion
Apr 2011 (Actual)
Completion
Feb 2012 (Actual)
Last update posted
May 16, 2024

2009 – 2012

United States locations

U.S. sites
37
U.S. states
22
U.S. cities
35
Facility City State ZIP Site status
Pfizer Investigational Site Huntsville Alabama 35801 —
Pfizer Investigational Site Tucson Arizona 85704 —
Pfizer Investigational Site San Diego California 92108 —
Pfizer Investigational Site Santa Maria California 93454 —
Pfizer Investigational Site Colorado Springs Colorado 80910 —
Pfizer Investigational Site Gainesville Florida 32607 —
Pfizer Investigational Site Jacksonville Florida 32216 —
Pfizer Investigational Site Sarasota Florida 34239 —
Pfizer Investigational Site Tampa Florida 33614 —
Pfizer Investigational Site Zephyrhills Florida 33542 —
Pfizer Investigational Site Morton Grove Illinois 60053 —
Pfizer Investigational Site Dubuque Iowa 52002 —
Pfizer Investigational Site Lexington Kentucky 40536 —
Pfizer Investigational Site Baltimore Maryland 21224-6821 —
Pfizer Investigational Site Wheaton Maryland 20902 —
Pfizer Investigational Site Worcester Massachusetts 01605 —
Pfizer Investigational Site Bingham Farms Michigan 48025 —
Pfizer Investigational Site Kalamazoo Michigan 49048 —
Pfizer Investigational Site Edina Minnesota 55435 —
Pfizer Investigational Site Columbia Missouri 65203 —
Pfizer Investigational Site Columbia Missouri 65212 —
Pfizer Investigational Site Lee's Summit Missouri 64086 —
Pfizer Investigational Site Omaha Nebraska 68114 —
Pfizer Investigational Site Omaha Nebraska 68134 —
Pfizer Investigational Site Albany New York 12206 —
Pfizer Investigational Site Binghamton New York 13905 —
Pfizer Investigational Site Syracuse New York 13210 —
Pfizer Investigational Site Dayton Ohio 45417 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15213 —
Pfizer Investigational Site Wyomissing Pennsylvania 19610 —
Pfizer Investigational Site Greenville South Carolina 29601 —
Pfizer Investigational Site Knoxville Tennessee 37909-1900 —
Pfizer Investigational Site Dallas Texas 75231 —
Pfizer Investigational Site Houston Texas 77074 —
Pfizer Investigational Site San Antonio Texas 78217 —
Pfizer Investigational Site Clarksburg West Virginia 26301 —
Pfizer Investigational Site Franklin Wisconsin 53132 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 78 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00847613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 16, 2024 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00847613 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →